Home > Publications database > Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. > print

001     147341
005     20240229123022.0
024 7 _ |a 10.1200/JCO.19.00577
|2 doi
024 7 _ |a pmid:31609649
|2 pmid
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:68456852
|2 altmetric
037 _ _ |a DKFZ-2019-02462
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Begemann, Matthias
|b 0
245 _ _ |a Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma.
260 _ _ |a Alexandria, Va.
|c 2020
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1578407797_25127
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jan 1;38(1):43-50.
520 _ _ |a The identification of a heritable tumor predisposition often leads to changes in management and increased surveillance of individuals who are at risk; however, for many rare entities, our knowledge of heritable predisposition is incomplete.Families with childhood medulloblastoma, one of the most prevalent childhood malignant brain tumors, were investigated to identify predisposing germline mutations. Initial findings were extended to genomes and epigenomes of 1,044 medulloblastoma cases from international multicenter cohorts, including retrospective and prospective clinical studies and patient series.We identified heterozygous germline mutations in the G protein-coupled receptor 161 (GPR161) gene in six patients with infant-onset medulloblastoma (median age, 1.5 years). GPR161 mutations were exclusively associated with the sonic hedgehog medulloblastoma (MBSHH) subgroup and accounted for 5% of infant MBSHH cases in our cohorts. Molecular tumor profiling revealed a loss of heterozygosity at GPR161 in all affected MBSHH tumors, atypical somatic copy number landscapes, and no additional somatic driver events. Analysis of 226 MBSHH tumors revealed somatic copy-neutral loss of heterozygosity of chromosome 1q as the hallmark characteristic of GPR161 deficiency and the primary mechanism for biallelic inactivation of GPR161 in affected MBSHH tumors.Here, we describe a novel brain tumor predisposition syndrome that is caused by germline GPR161 mutations and characterized by MBSHH in infants. Additional studies are needed to identify a potential broader tumor spectrum associated with germline GPR161 mutations.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Waszak, Sebastian M
|b 1
700 1 _ |a Robinson, Giles W
|b 2
700 1 _ |a Jäger, Natalie
|0 P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3
|b 3
|u dkfz
700 1 _ |a Sharma, Tanvi
|0 P:(DE-He78)36e1ec4777d5b7887344177dca41eae9
|b 4
|u dkfz
700 1 _ |a Knopp, Cordula
|b 5
700 1 _ |a Kraft, Florian
|b 6
700 1 _ |a Moser, Olga
|b 7
700 1 _ |a Mynarek, Martin
|b 8
700 1 _ |a Guerrini-Rousseau, Lea
|b 9
700 1 _ |a Brugieres, Laurence
|b 10
700 1 _ |a Varlet, Pascale
|b 11
700 1 _ |a Pietsch, Torsten
|b 12
700 1 _ |a Bowers, Daniel C
|b 13
700 1 _ |a Chintagumpala, Murali
|b 14
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 15
|u dkfz
700 1 _ |a Korbel, Jan O
|b 16
700 1 _ |a Rutkowski, Stefan
|b 17
700 1 _ |a Eggermann, Thomas
|b 18
700 1 _ |a Gajjar, Amar
|b 19
700 1 _ |a Northcott, Paul
|b 20
700 1 _ |a Elbracht, Miriam
|b 21
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 22
|u dkfz
700 1 _ |a Kontny, Udo
|b 23
700 1 _ |a Kurth, Ingo
|b 24
773 _ _ |a 10.1200/JCO.19.00577
|g p. JCO.19.00577 -
|0 PERI:(DE-600)2005181-5
|n 1
|p 43-50
|t Journal of clinical oncology
|v 38
|y 2020
|x 1527-7755
909 C O |p VDB
|o oai:inrepo02.dkfz.de:147341
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)36e1ec4777d5b7887344177dca41eae9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b J CLIN ONCOL : 2017
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21